The company said it filed a prospectus supplement on March 14, 2024 to its Form S-3 automatic shelf registration statement (Registration No. 333-276954).

1. 01

   The company said it filed a prospectus supplement on March 14, 2024 to its Form S-3 automatic shelf registration statement (Registration No. 333-276954).

2. 02

   The company said the prospectus supplement covers the resale of up to 6,546,873 shares of common stock, par value $1.00 per share. These shares may be issued upon the exchange of DOC DR, LLC non-managing member units.

3. 03

   The company said the shares may be issued upon the exchange of 6,546,913.828 DOC DR, LLC non-managing member units, subject to the redemption rights under the Operating Agreement dated March 1, 2024.

4. 04

   The company said it filed this Form 8-K to provide a legal opinion from its counsel, Ballard Spahr LLP, on the legality of the securities covered by the prospectus supplement. The opinion is attached as Exhibit 5.1.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.